Insulin resistance and chronic kidney disease;Insulinorésistance et insuffisance rénale chronique

Nephrologie et Therapeutique

Volumn 4, Issue 7, 2008, Pages 568-574

  Chauveau, Philippe ^a   Rigalleau, Vincent ^b   Aparicio, Michel ^a  

^a HÔPITAL PELLEGRIN   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Chronic kidney disease; Insulin resistance

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLYCOGEN; ICODEXTRIN; INSULIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; VITAMIN D;

AEROBIC METABOLISM; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; ENDOTHELIUM; GLUCOSE UTILIZATION; HOMEOSTASIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC ACIDOSIS; METABOLIC DISORDER; METABOLISM; PHYSICAL ACTIVITY; RISK; SHORT SURVEY; SKELETAL MUSCLE; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY;

ACIDOSIS; DISEASE PROGRESSION; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; PROTEINS; VITAMIN D DEFICIENCY;

EID: 57049134118     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2008.03.010     Document Type: Short Survey

References (58)

1. Fliser D., Pacini G., Engelleiter R., Kautzky-Willer A., Prager R., Franek E., et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 53 5 (1998 May) 1343-1347
2. DeFronzo R.A., Alvestrand A., Smith D., Hendler R., Hendler E., and Wahren J. Insulin resistance in uremia. J Clin Invest 67 2 (1981 Feb) 563-568
3. Despres J.P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Moorjani S., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 15 (1996 Apr 11) 952-957
4. DeFronzo R.A., Tobin J.D., and Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237 3 (1979 Sep) E214-E223
5. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 1 (2000 Jan) 57-63
6. Catena C., Soardo G., Melis A., De Marchi S., and Sechi L.A. Glucose metabolism in early renal failure. Am J Kidney Dis 46 2 (2005 Aug) 367 author reply-8
7. Becker B., Kronenberg F., Kielstein J.T., Haller H., Morath C., Ritz E., et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 16 4 (2005 Apr) 1091-1098
8. Chonchol M., and Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int 71 2 (2007 Jan) 134-139
9. Reaven G.M. The metabolic syndrome: is this diagnosis necessary?. Am J Clin Nutr 83 6 (2006 Jun) 1237-1247
10. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int 62 (Suppl. 1997 Nov) S48-S52
11. Rigalleau V., and Gin H. Carbohydrate metabolism in uraemia. Curr Opin Clin Nutr Metab Care 8 4 (2005 Jul) 463-469
12. Rigalleau V., Combe C., Blanchetier V., Aubertin J., Aparicio M., and Gin H. Low protein diet in uremia: effects on glucose metabolism and energy production rate. Kidney Int 51 4 (1997 Apr) 1222-1227
13. Rigalleau V., Baillet L., Lasseur C., Moreau K., Chauveau P., Aparicio M., et al. Splanchnic tissues play a crucial role in uremic glucose intolerance. J Ren Nutr 13 3 (2003 Jul) 212-218
14. Mak R.H., Bettinelli A., Turner C., Haycock G.B., and Chantler C. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab 60 2 (1985 Feb) 229-233
15. McCaleb M.L., Izzo M.S., and Lockwood D.H. Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest 75 2 (1985 Feb) 391-396
16. Kraus L.M., Traxinger R., and Kraus A.P. Uremia and insulin resistance: N-carbamoyl-asparagine decreases insulin-sensitive glucose uptake in rat adipocytes. Kidney Int 65 3 (2004 Mar) 881-887
17. Oimomi M., Hatanaka H., Yoshimura Y., Yokono K., Baba S., and Taketomi Y. Carbamylation of insulin and its biological activity. Nephron 46 1 (1987) 63-66
18. Kobayashi S., Maejima S., Ikeda T., and Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 15 1 (2000 Jan) 65-70
19. Aparicio M., Gin H., Potaux L., Bouchet J.L., Morel D., and Aubertin J. Effect of a ketoacid diet on glucose tolerance and tissue insulin sensitivity. Kidney Int 27 (Suppl. 1989 Nov) S231-S235
20. DeFronzo R.A., and Beckles A.D. Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol 236 4 (1979 Apr) E328-E334
21. Kobayashi S., Maesato K., Moriya H., Ohtake T., and Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis 45 2 (2005 Feb) 275-280
22. Reaich D., Channon S.M., Scrimgeour C.M., Daley S.E., Wilkinson R., and Goodship T.H. Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am J Physiol 265 2 Pt 1 (1993 Aug) E230-E235
23. Zittermann A. Serum 25-hydroxyvitamin D response to oral vitamin D intake in children. Am J Clin Nutr 78 3 (2003 Sep) 496-497
24. Kautzky-Willer A., Pacini G., Barnas U., Ludvik B., Streli C., Graf H., et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 47 1 (1995 Jan) 200-206
25. Zoccali C., Mallamaci F., and Tripepi G. Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney Int 84 (Suppl. 2003 May) S65-S68
26. Shoelson S.E., Lee J., and Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 116 7 (2006 Jul) 1793-1801
27. Shen Y., Peake P.W., and Kelly J.J. Should we quantify insulin resistance in patients with renal disease?. Nephrology (Carlton) 10 6 (2005 Dec) 599-605
28. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 58 4 (2000 Oct) 1703-1710
29. De Feo P., Volpi E., Lucidi P., Cruciani G., Reboldi G., Siepi D., et al. Physiological increments in plasma insulin concentrations have selective and different effects on synthesis of hepatic proteins in normal humans. Diabetes 42 7 (1993 Jul) 995-1002
30. Guebre-Egziabher F., Drai J., and Fouque D. Adiponectin and chronic kidney disease. J Ren Nutr 17 1 (2007 Jan) 9-12
31. Dogra G., Irish A., Chan D., and Watts G. Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD. Am J Kidney Dis 48 6 (2006 Dec) 926-934
32. Shinohara K., Shoji T., Emoto M., Tahara H., Koyama H., Ishimura E., et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13 7 (2002 Jul) 1894-1900
33. Cano N.J., Roth H., Aparicio M., Azar R., Canaud B., Chauveau P., et al. Malnutrition in hemodialysis diabetic patients: evaluation and prognostic influence. Kidney Int 62 2 (2002 Aug) 593-601
34. Pupim L.B., Flakoll P.J., Majchrzak K.M., Aftab Guy D.L., Stenvinkel P., and Ikizler T.A. Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int 68 4 (2005 Oct) 1857-1865
35. Siew E.D., Pupim L.B., Majchrzak K.M., Shintani A., Flakoll P.J., and Ikizler T.A. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 71 2 (2007 Jan) 146-152
36. Lee S.W., Park G.H., Song J.H., Hong K.C., and Kim M.J. Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol Dial Transplant 22 9 (2007 Sep) 2554-2562
37. Chevalier S., Burgess S.C., Malloy C.R., Gougeon R., Marliss E.B., and Morais J.A. The greater contribution of gluconeogenesis to glucose production in obesity is related to increased whole-body protein catabolism. Diabetes 55 3 (2006 Mar) 675-681
38. Wang X., Hu Z., Hu J., Du J., and Mitch W.E. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 147 9 (2006 Sep) 4160-4168
39. Kubo M., Kiyohara Y., Kato I., Iwamoto H., Nakayama K., Hirakata H., et al. Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study. Kidney Int 55 6 (1999 Jun) 2450-2456
40. Chen J., Muntner P., Hamm L.L., Fonseca V., Batuman V., Whelton P.K., et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14 2 (2003 Feb) 469-477
41. Hadjadj S., Pean F., Gallois Y., Passa P., Aubert R., Weekers L., et al. Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the Genesis France-Belgium Study. Diabetes Care 27 11 (2004 Nov) 2661-2668
42. Fujikawa R., Okubo M., Egusa G., and Kohno N. Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow up study. Diabetes Res Clin Pract 53 2 (2001 Aug) 99-106
43. Kaartinen K., Syrjanen J., Porsti I., Harmoinen A., Pasternack A., Huhtala H., et al. Insulin resistance and the progression of IgA glomerulonephritis. Nephrol Dial Transplant 22 3 (2007 Mar) 778-783
44. Dengel D.R., Goldberg A.P., Mayuga R.S., Kairis G.M., and Weir M.R. Insulin resistance, elevated glomerular filtration fraction, and renal injury. Hypertension 28 1 (1996 Jul) 127-132
45. Oterdoom L.H., de Vries A.P., Gansevoort R.T., de Jong P.E., Gans R.O., and Bakker S.J. Fasting insulin modifies the relation between age and renal function. Nephrol Dial Transplant 22 6 (2007 Jun) 1587-1592
46. Miyazaki Y., Cersosimo E., Triplitt C., and DeFronzo R.A. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 72 11 (2007 Dec) 1367-1373
47. DeFronzo R.A., Sherwin R.S., and Kraemer N. Effect of physical training on insulin action in obesity. Diabetes 36 12 (1987 Dec) 1379-1385
48. Garcia-Lopez E., Carrero J.J., Suliman M.E., Lindholm B., and Stenvinkel P. Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 27 Suppl. 2 (2007 Jun) S205-S209
49. Amici G., Orrasch M., Da Rin G., and Bocci C. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 17 (2001) 80-83
50. Pajek J., Kveder R., Bren A., Gucek A., Ihan A., Osredkar J., et al. Short-term effects of a new bicarbonate/lactate-buffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit Dial Int 28 1 (2008 Jan-Feb) 44-52
51. McFarlane S.I., Kumar A., and Sowers J.R. Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 91 12A (2003 Jun 19) 30H-37H
52. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 9311 (2002 Mar 23) 1004-1010
53. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., and Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86 1 (2001 Jan) 280-288
54. Horio T., Suzuki M., Takamisawa I., Suzuki K., Hiuge A., Yoshimasa Y., et al. Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am J Hypertens 18 12 Pt 1 (2005 Dec) 1626-1630
55. Voytovich M.H., Simonsen C., Jenssen T., Hjelmesaeth J., Asberg A., and Hartmann A. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 20 2 (2005 Feb) 413-418
56. Lin S.H., Lin Y.F., Kuo S.W., Hsu Y.J., and Hung Y.J. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kidney Dis 42 4 (2003 Oct) 774-780
57. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 24 (2007 Jun 14) 2457-2471
58. Rzonca S.O., Suva L.J., Gaddy D., Montague D.C., and Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145 1 (2004 Jan) 401-406